JAHA:PCI术后血栓形成风险高的患者出血风险也会高

2018-05-23 MedSci MedSci原创

经皮冠脉介入术后的血栓和出血风险的评估对于指导抗血栓治疗至关重要。本研究纳入了CREDO‐Kyoto数据库中的4778名患者,并在RESET与NEXT数据库中的4669名患者中进行重复确认,主要血栓形成和出血事件为心梗、支架血栓或缺血性卒中。在预测血栓形成的评分中,慢性肾脏疾病、房颤、外周血管疾病和贫血为2分,年龄≥75岁、心衰、糖尿病和慢性完全闭塞为1分,在预测出血事件的评分中,血小板减少症、严

经皮冠脉介入术后的血栓和出血风险的评估对于指导抗血栓治疗至关重要。

本研究纳入了CREDO‐Kyoto数据库中的4778名患者,并在RESET与NEXT数据库中的4669名患者中进行重复确认,主要血栓形成和出血事件为心梗、支架血栓或缺血性卒中。在预测血栓形成的评分中,慢性肾脏疾病、房颤、外周血管疾病和贫血为2分,年龄≥75岁、心衰糖尿病和慢性完全闭塞为1分,在预测出血事件的评分中,血小板减少症、严重的慢性肾脏疾病、外周血管疾病和心衰为2分,原发性心梗、恶性肿瘤和房颤为1分。分析结果显示,血栓形成风险评分≥4(n=682)的患者三年内发生血栓形成事件的风险要明显更高(P<0.0001),出血风险评分≥3(n=666)的患者发生出血风险要明显更高(P<0.0001)。此外,在682名高风险血栓形成的患者中,仅有39名患者(5.7%)是低出血风险,有401名(58.8%)患者出血风险是高的。

研究结果显示,CREDO‐Kyoto评分体系对经皮冠脉介入术后的血栓和出血风险的评估有较好的危险分层作用,且大部分血栓形成风险高的患者出血风险也高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633834, encodeId=fbc216338346b, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Oct 22 21:10:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267827, encodeId=b329126e827ca, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486428, encodeId=074a1486428d5, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317859, encodeId=544c31e85900, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed May 23 13:15:52 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-10-22 zxl736
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633834, encodeId=fbc216338346b, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Oct 22 21:10:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267827, encodeId=b329126e827ca, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486428, encodeId=074a1486428d5, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317859, encodeId=544c31e85900, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed May 23 13:15:52 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-25 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633834, encodeId=fbc216338346b, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Oct 22 21:10:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267827, encodeId=b329126e827ca, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486428, encodeId=074a1486428d5, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317859, encodeId=544c31e85900, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed May 23 13:15:52 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633834, encodeId=fbc216338346b, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Mon Oct 22 21:10:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267827, encodeId=b329126e827ca, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486428, encodeId=074a1486428d5, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 25 04:10:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317859, encodeId=544c31e85900, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed May 23 13:15:52 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-23 wzb521zf

    一起学习学习

    0

相关资讯

JAHA:电生理手术对患者的辐射暴露问题不容忽视!

本研究的目的旨在大样本病人数据中评估电生理或器械植入术中X线暴露的情况和比较不同技术的房颤消融术对患者的X线暴露情况。本研究纳入了6095例接受电生理检查的患者和2055例器械植入的患者,经过7年时间的分析评估,发现电生理检查的X线暴露量、剂量面积乘积与有效剂量呈逐年下降趋势(p<0.001),通过分析2416例房颤消融术,发现7名不同的有经验的操作者在X线暴露量、剂量面积乘积与有效剂量方面存在明

JACC:主要不良肢体事件可明显增加外周动脉疾病患者死亡风险

下肢外周动脉疾病(PAD)患者发生主要心血管不良事件(MACE)和主要不良肢体事件(MALE)的风险要更高,然而关于发生MALE患者的预后信息了解甚少。本研究纳入了COMPASS临床试验中的6391例PAD患者,MALE定义为需要介入治疗或截肢的严重的肢体局部缺血。随访结果显示,共有128例患者发生了主要不良肢体事件,经历了MALE之后,1年的累积住院率为61.5%,血管截肢率为20.5%,死亡率

晕厥,这九大常见病因你知道吗?

晕厥是指一过性全脑血液低灌注导致的短暂意识丧失,特点为发生迅速、一过性、自限性并能够完全恢复。晕厥是临床上的常见症状,临床上导致晕厥的病因很多,机制较为复杂,下面对其常见的病因进行介绍。

盘点:JACC5月第4期研究一览

1. 卡维地洛可用于预防化疗引起的心脏毒性DOI: 10.1016/j.jacc.2018.02.049蒽环霉素(ANT)化疗有一定的心脏毒性,β受体阻滞剂预防该心脏毒性的效果尚存在争议。本研究纳入了200例HER2阴性且左室射血分数正常的接受ANT化疗的乳腺癌患者,并将其随机分成卡维地洛治疗组和安慰剂组,主要终点事件是6个月内LVEF减少10%以上,次要终点事件是卡维地洛对肌钙蛋白I和B型钠尿肽

Lancet:全美糖尿病并发症死亡率变化趋势(1985-2015)

研究发现,由于糖尿病临床管理、预防和疾病监测的进步,美国糖尿病患者的心血管并发症及死亡风险显著降低

JACC:隐发性卒中患者需不需要进行卵圆孔封堵?

对于隐发性卒中患者,卵圆孔(PFO)封堵术是否能获益尚存在争议。本研究的目的旨在评估卵圆孔封堵术的获益情况是否与PFO的形态特征有关。本研究共纳入了120名(平均年龄51.8岁)隐发性卒中伴高风险PFO患者,高风险PFO定义为PFO伴房隔瘤、运动度过大或大小≥2 mm,将患者随机分成经导管PFO封堵组和药物治疗组,平均随访时间是2年,主要终点事件是卒中、血管源性死亡和大出血的组合事件。随访结果发现